Published in J Clin Endocrinol Metab on December 01, 1982
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
The pathobiology of the osteoclast. J Clin Pathol (1985) 1.48
Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest (1988) 1.48
Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest (1986) 0.82
Parathyroid Hormone-related Protein in Breast Cancer Tissues: Relationship between Primary and Metastatic Sites. Breast Cancer (1994) 0.78
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol (1990) 7.27
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet (2001) 2.37
Hands across the equator: the Hereford-Muheza link eight years on. BMJ (1994) 2.32
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother (1999) 2.02
Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J (1999) 1.99
Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2001) 1.90
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
Biology of Toxoplasma gondii. AIDS (1993) 1.79
Noncondylomatous cervical wart virus infection. Obstet Gynecol (1980) 1.79
Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med (1978) 1.76
Effect of severe, chronic illness on thyroid function. Lancet (1974) 1.61
The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 1.57
Susceptibility to chronic infection with Toxoplasma gondii does not correlate with susceptibility to acute infection in mice. Infect Immun (1993) 1.56
Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int (1997) 1.51
Klinefelter's syndrome with hypogonadotrophic hypogonadism. Br Med J (1977) 1.50
Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore. Singapore Med J (2008) 1.48
Current management of malignant melanoma. Ann Surg (1993) 1.47
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res (1999) 1.47
Superior oblique paralysis. A review of 270 cases. Arch Ophthalmol (1986) 1.45
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res (2001) 1.44
1000 femoral neck fractures: the effect of pre-injury mobility and surgical experience on outcome. Injury (1994) 1.43
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology (2000) 1.43
The aetiology of Dupuytren's disease. Br J Hosp Med (1986) 1.42
Preservation surgery for malignant disease: why it works. South Med J (1989) 1.42
Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care (1989) 1.41
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology (2001) 1.41
Measurement of bone in the os calcis: a clinical evaluation. J Bone Miner Res (1989) 1.39
Diabetes to the year 2000 and beyond. National Action Plan. Med J Aust (1993) 1.38
Difficult airway alert. Anaesthesia (2003) 1.38
Host resistance to carcinoma of the breast. South Med J (1980) 1.37
Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA (2000) 1.37
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun (1998) 1.33
Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Trop (1997) 1.33
Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis (1996) 1.32
Natural antibody in mammalian serum reacting with an antigen in some leptospires. J Bacteriol (1968) 1.32
Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med (1994) 1.30
E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res (1996) 1.30
Necrotizing fasciitis in rheumatic diseases. Lupus (2006) 1.26
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum (2006) 1.25
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene (2011) 1.24
A monomeric red fluorescent protein with low cytotoxicity. Nat Commun (2012) 1.22
Comparison of peak flow gauge and peak flow meter. Thorax (1975) 1.21
Abortion due to infection with Chlamydia psittaci in a sheep farmer's wife. Br Med J (Clin Res Ed) (1985) 1.20
Prediction of oesophagogastric varices in patients with liver cirrhosis. J Gastroenterol Hepatol (1999) 1.18
Persistence and not recurrence when a tumor appears at the site of resection. Surgery (1989) 1.17
On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol (1983) 1.17
Quantitative bone histology: a new method. Pathology (1980) 1.15
Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore. J Infect Dis (1997) 1.15
Bone mass is low in relatives of osteoporotic patients. Ann Intern Med (1988) 1.14
Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin. Infect Immun (1998) 1.14
Electron microscopic detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. Acta Cytol (1979) 1.14
Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther (2001) 1.11
Osteocyte death and hip fracture. Calcif Tissue Int (1993) 1.11
Use of oral mannitol in the oedematous patient. Br Med J (1970) 1.11
Urinary excretion of calcium and magnesium in patients with calcium-containing renal stones. Lancet (1967) 1.09
Ectopic penile testis. Urology (1976) 1.08
An automatic device for sampling digesta from the duodenum of the sheep. Res Vet Sci (1971) 1.07
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem (1999) 1.07
Acute placentitis and spontaneous abortion caused by chlamydia psittaci of sheep origin: a histological and ultrastructural study. J Clin Pathol (1985) 1.07
Idiopathic rupture of the bladder. J Urol (1976) 1.06
The significance of noncondylomatous wart virus infection of the cervical transformation zone. A review with discussion of two illustrative cases. Acta Cytol (1979) 1.06
The association between Porphyromonas gingivalis-specific maternal serum IgG and low birth weight. J Periodontol (2001) 1.06
Retroperitoneal collections--aetiology and radiological implications. Clin Radiol (1997) 1.05
Circulating thyroid hormone levels in children. Arch Dis Child (1977) 1.05
Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess. Aliment Pharmacol Ther (2002) 1.04
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res (2000) 1.03
Natural killer cells and the Guy's Hospital trials. Arch Surg (1988) 1.03
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res (2001) 1.03
Familial cavernous angiomas: natural history and genetic study over a 5-year period. Am J Med Genet (1982) 1.01
Recovery from steroid-induced osteoporosis. Ann Intern Med (1987) 1.01
Scalp markers for precise craniotomy siting, using computed tomography. J Comput Assist Tomogr (1979) 1.00
Thyroid abnormalities in patients with myotonic dystrophy. Clin Endocrinol (Oxf) (1982) 1.00
Cytokines, Toxoplasma and intracellular parasitism. Immunol Rev (1992) 0.99
Circulating thyroid hormone concentrations and posture and venous compression. Br Med J (1975) 0.98
Clinical stage I melanoma among patients who presented with lesions of Clark levels deep III through V. Ann Surg (1988) 0.98
Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. Clin Endocrinol (Oxf) (1976) 0.98
Immobilisation hypercalcemia. Miner Electrolyte Metab (1984) 0.97
The "seed and soil" hypothesis and the decline of radical surgery: a surgeon's opinion. Tex Med (1990) 0.97
The response of the rat tibial growth plates to distal periosteal division. J Anat (1987) 0.97
Bone loss after liver transplantation. Hepatology (1991) 0.97
Cellular activation through the ligation of intercellular adhesion molecule-1. J Cell Sci (1998) 0.97